The world's first oral GLP-1 receptor agonist, Novo-Nordisk A/S, has been fully launched in China.

On January 11, Gelonghui reported that Novo-Nordisk A/S announced the comprehensive launch of its Innovative Drug, Ozempic (semaglutide tablets), in China today. As the first oral GLP-1RA, Ozempic combines SNAC technology to achieve significant benefits such as lowering blood sugar, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will improve patient adherence, creating a new era in the treatment of type 2 diabetes, helping achieve quality blood sugar targets and comprehensive metabolic management, bringing new hope to 0.14 billion diabetes patients in China.

Gelonghui FinanceJan 11 18:10

Express News | Novo-Nordisk A/S is confident in the economic prospects of China and its development in the country, and is willing to continue investing in the Chinese market.

BreakingsJan 11 09:41

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading

MT NewswiresJan 11 00:17

U.S. stocks are experiencing fluctuations | Novo-Nordisk A/S (NVO.US) is rising nearly 2% against the trend while developing weight-loss drugs using AI.

On Friday, Novo-Nordisk A/S (NVO.US) rose nearly 2% against the trend, closing at $86.77.

Zhitong FinanceJan 10 23:11

Novo Holdings Invests in $200M Series A for Windward Bio Launch to Advance Long-acting Treatments for Asthma and COPD

PR NewswireJan 10 22:29

HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review

Seeking AlphaJan 10 21:56